10-Q quarterly report · filed Nov 2, 2026

Krystal Biotech, Inc. (KRYS) Q3 2026 10-Q Quarterly Report

Short answer

Krystal Biotech, Inc. (KRYS) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $127M (up 30.2% year over year) with net income of $63M.

Q3 2026 key financials · XBRL

Revenue
$127M
+30.2% YoY · +6.8% QoQ
Net income
$63M
−20.5% YoY · +15.2% QoQ
Operating margin
55.9%
EPS (diluted)
$2.04
−23.3% YoY · +14.0% QoQ

Source: XBRL data from the Krystal Biotech, Inc. (KRYS) Q3 2026 10-Q on SEC EDGAR. USD.

Krystal Biotech, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 product revenue $127.3M, up $29.5M from $97.8M, driven by Europe and Japan launches
  • Gross margin 94%; operating income $71.1M vs $41.4M, net income $63.1M vs $79.4M
  • VYJUVEK strongest product line, $127.3M quarterly revenue; no comparable segment breakdown disclosed
  • Cash, cash equivalents and short-term investments $911.9M; operating cash flow $246.4M year-to-date
  • $400M share repurchase authorized; France pricing negotiations extend until at least 2027, EMERALD-1 enrollment slower than anticipated

Risk Factors

  • New risk: $400 million stock repurchase program authorized in October 2026
  • Most material update: repurchases may reduce cash available for clinical programs and VYJUVEK commercialization
  • Regulatory risk: repurchases may incur a 1% U.S. federal excise tax
  • Market risk: suspended or discontinued repurchases could adversely affect stock price
  • Financial risk: program could diminish cash reserves without enhancing long-term stockholder value

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Krystal Biotech, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.